Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B

Journal of Hepatology

Volumn 54, Issue 1, 2011, Pages 12-18

  Chotiyaputta, Watcharasak ^a   Peterson, Carolyn ^b   Ditah, Fausta A ^a   Goodwin, Diane ^b   Lok, Anna S F ^a,c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b GILEAD SCIENCES   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d DUKE UNIVERSITY HOSPITAL   (United States)

Author keywords

Adefovir dipivoxil; Antiviral resistance; Compliance; Entecavir; Lamivudine; Tenofovir disoproxil fumarate

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TENOFOVIR;

ADOLESCENT; ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

ADENINE; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78649631236     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.06.016     Document Type: Article

References (35)

1. A.S. Lok, F. Zoulim, S. Locarnini, A. Bartholomeusz, M.G. Ghany, and J.M. Pawlotsky Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 2007 254 265
2. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, and Z. Krastev Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
3. C.E. Westland, H. Yang, Delaney. WEt, C.S. Gibbs, M.D. Miller, and M. Wulfsohn Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B Hepatology 38 2003 96 103
4. P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, and M.L. Shiffman Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816 (Pubitemid 36245757)
5. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807 (Pubitemid 36245756)
6. T.T. Chang, R.G. Gish, R. de Man, A. Gadano, J. Sollano, and Y.C. Chao A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010 (Pubitemid 43357804)
7. C.L. Lai, D. Shouval, A.S. Lok, T.T. Chang, H. Cheinquer, and Z. Goodman Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020 (Pubitemid 43357805)
8. C.L. Lai, E. Gane, Y.F. Liaw, C.W. Hsu, S. Thongsawat, and Y. Wang Telbivudine versus lamivudine in patients with chronic hepatitis B N Engl J Med 357 2007 2576 2588
9. F. Maggiolo, L. Ravasio, D. Ripamonti, G. Gregis, G. Quinzan, and C. Arici Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors Clin Infect Dis 40 2005 158 163
10. D.L. Paterson, S. Swindells, J. Mohr, M. Brester, E.N. Vergis, and C. Squier Adherence to protease inhibitor therapy and outcomes in patients with HIV infection Ann Intern Med 133 2000 21 30
11. D.R. Bangsberg, E.P. Acosta, R. Gupta, D. Guzman, E.D. Riley, and P.R. Harrigan Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness AIDS 20 2006 223 231
12. J.B. Nachega, M. Hislop, D.W. Dowdy, R.E. Chaisson, L. Regensberg, and G. Maartens Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes Ann Intern Med 146 2007 564 573
13. K. Schroeder, T. Fahey, and S. Ebrahim How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials Arch Intern Med 164 2004 722 732
14. T.J. Bramley, P.P. Gerbino, B.S. Nightengale, and F. Frech-Tamas Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations J Manag Care Pharm 12 2006 239 245
15. V. Fung, J. Huang, R. Brand, J.P. Newhouse, and J. Hsu Hypertension treatment in a medicare population: adherence and systolic blood pressure control Clin Ther 29 2007 972 984
16. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N Engl J Med 335 1996 1001 1009
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
18. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, and P.A. Beere Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
19. C.A. Jackevicius, M. Mamdani, and J.V. Tu Adherence with statin therapy in elderly patients with and without acute coronary syndromes JAMA 288 2002 462 467
20. J.S. Benner, R.J. Glynn, H. Mogun, P.J. Neumann, M.C. Weinstein, and J. Avorn Long-term persistence in use of statin therapy in elderly patients JAMA 288 2002 455 461
21. H. Liu, C.E. Golin, L.G. Miller, R.D. Hays, C.K. Beck, and S. Sanandaji A comparison study of multiple measures of adherence to HIV protease inhibitors Ann Intern Med 134 2001 968 977
22. C.W. Cheng, K.S. Woo, J.C. Chan, B. Tomlinson, and J.H. You Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device Am J Health Syst Pharm 62 2005 411 415
23. S.R. Erickson, J.H. Coombs, D.M. Kirking, and A.R. Azimi Compliance from self-reported versus pharmacy claims data with metered-dose inhalers Ann Pharmacother 35 2001 997 1003
24. A. Kwon, K.M. Bungay, Y. Pei, W.H. Rogers, I.B. Wilson, and Q. Zhou Antidepressant use: concordance between self-report and claims records Med Care 41 2003 368 374
25. M. Veronesi, A.F. Cicero, M.G. Prandin, A. Dormi, E. Cosentino, and E. Strocchi A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice Vasc Health Risk Manag 3 2007 999 1005
26. J.J. Caro, M. Salas, J.L. Speckman, G. Raggio, and J.D. Jackson Persistence with treatment for hypertension in actual practice CMAJ 160 1999 31 37
27. S. Perreault, D. Lamarre, L. Blais, A. Dragomir, D. Berbiche, and L. Lalonde Persistence with treatment in newly treated middle-aged patients with essential hypertension Ann Pharmacother 39 2005 1401 1408
28. B.L. van Wijk, W.H. Shrank, O.H. Klungel, S. Schneeweiss, M.A. Brookhart, and J. Avorn A cross-national study of the persistence of antihypertensive medication use in the elderly J Hypertens 26 2008 145 153 (Pubitemid 350294860)
29. A. Helin-Salmivaara, P. Lavikainen, M.J. Korhonen, H. Halava, S.Y. Junnila, and R. Kettunen Long-term persistence with statin therapy: a nationwide register study in Finland Clin Ther 30 2008 2228 2240
30. S.M. Abughosh, S.J. Kogut, S.E. Andrade, P. Larrat, and J.H. Gurwitz Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients J Manag Care Pharm 10 2004 404 411
31. A.K. Mantel-Teeuwisse, W.G. Goettsch, O.H. Klungel, A. de Boer, and R.M. Herings Long term persistence with statin treatment in daily medical practice Heart 90 2004 1065 1066
32. S. Perreault, L. Blais, D. Lamarre, A. Dragomir, D. Berbiche, and L. Lalonde Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention Br J Clin Pharmacol 59 2005 564 573
33. L.A. Donnelly, A.S. Doney, A.D. Morris, C.N. Palmer, and P.T. Donnan Long-term adherence to statin treatment in diabetes Diabet Med 25 2008 850 855
34. J.B. Nachega, M. Hislop, D.W. Dowdy, M. Lo, S.B. Omer, and L. Regensberg Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults J Acquir Immune Defic Syndr 43 2006 78 84
35. A.J. Levine, C.H. Hinkin, S.A. Castellon, K.I. Mason, M.N. Lam, and A. Perkins Variations in patterns of highly active antiretroviral therapy (HAART) adherence AIDS Behav 9 2005 355 362